Stryker Corporation $SYK Stock Holdings Boosted by DNB Asset Management AS

DNB Asset Management AS lifted its position in Stryker Corporation (NYSE:SYK) by 5.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 75,107 shares of the medical technology company’s stock after buying an additional 3,733 shares during the period. DNB Asset Management AS’s holdings in Stryker were worth $29,715,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of SYK. Nuveen LLC acquired a new stake in Stryker in the 1st quarter valued at about $558,075,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Stryker by 9.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after purchasing an additional 1,021,496 shares in the last quarter. Alliancebernstein L.P. lifted its stake in Stryker by 66.7% during the first quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company’s stock valued at $511,152,000 after purchasing an additional 549,643 shares during the last quarter. ABN AMRO Bank N.V. acquired a new stake in Stryker during the second quarter valued at approximately $191,047,000. Finally, Vanguard Group Inc. boosted its holdings in Stryker by 1.3% during the second quarter. Vanguard Group Inc. now owns 33,500,571 shares of the medical technology company’s stock worth $13,253,831,000 after buying an additional 440,607 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on SYK. Sanford C. Bernstein reiterated an “outperform” rating on shares of Stryker in a research report on Monday, November 3rd. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $435.00 target price on shares of Stryker in a research report on Friday, November 14th. UBS Group set a $408.00 price target on Stryker in a research report on Monday, October 13th. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Finally, Barclays raised their target price on shares of Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Thirteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and a consensus target price of $434.37.

Stryker Trading Up 2.2%

Shares of NYSE SYK opened at $368.35 on Friday. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19. The business has a 50-day moving average price of $369.38 and a two-hundred day moving average price of $380.68. The firm has a market capitalization of $140.87 billion, a PE ratio of 48.79, a PEG ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The business had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm’s revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Insider Activity at Stryker

In related news, CFO Preston Wendell Wells sold 165 shares of the stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the completion of the sale, the chief financial officer directly owned 6,694 shares in the company, valued at approximately $2,449,200.72. This trade represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 276,173 shares of the business’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the transaction, the director owned 2,702,108 shares in the company, valued at $954,600,714.24. This trade represents a 9.27% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 522,618 shares of company stock worth $185,577,237. Corporate insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.